Ally Bridge Group NY LLC Sells 27,500 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)

Ally Bridge Group NY LLC reduced its position in shares of Sight Sciences, Inc. (NASDAQ:SGHTGet Rating) by 8.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 314,804 shares of the company’s stock after selling 27,500 shares during the quarter. Sight Sciences accounts for about 2.7% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 19th biggest holding. Ally Bridge Group NY LLC owned 0.66% of Sight Sciences worth $3,639,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. American International Group Inc. increased its stake in Sight Sciences by 87.2% during the 1st quarter. American International Group Inc. now owns 11,088 shares of the company’s stock valued at $128,000 after purchasing an additional 5,165 shares in the last quarter. MetLife Investment Management LLC bought a new stake in shares of Sight Sciences in the first quarter worth approximately $166,000. CNA Financial Corp grew its stake in shares of Sight Sciences by 16.8% in the first quarter. CNA Financial Corp now owns 16,383 shares of the company’s stock worth $189,000 after acquiring an additional 2,356 shares during the period. New York State Common Retirement Fund grew its stake in shares of Sight Sciences by 146.5% in the first quarter. New York State Common Retirement Fund now owns 17,497 shares of the company’s stock worth $202,000 after acquiring an additional 10,400 shares during the period. Finally, Rhumbline Advisers bought a new stake in shares of Sight Sciences in the first quarter worth approximately $205,000. 65.20% of the stock is currently owned by institutional investors.

Sight Sciences Stock Performance

Shares of NASDAQ SGHT opened at $7.45 on Friday. The firm has a 50 day moving average of $8.97 and a 200 day moving average of $10.07. The company has a current ratio of 16.73, a quick ratio of 16.38 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $356.30 million, a price-to-earnings ratio of -4.23 and a beta of 0.96. Sight Sciences, Inc. has a 12-month low of $6.25 and a 12-month high of $32.86.

Analysts Set New Price Targets

A number of brokerages have recently commented on SGHT. Morgan Stanley reduced their price target on shares of Sight Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, August 12th. Piper Sandler reduced their price target on shares of Sight Sciences from $17.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, August 12th. Finally, Stifel Nicolaus reiterated an “initiates” rating on shares of Sight Sciences in a research note on Tuesday, July 26th. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $18.50.

About Sight Sciences

(Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

Featured Stories

Want to see what other hedge funds are holding SGHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sight Sciences, Inc. (NASDAQ:SGHTGet Rating).

Institutional Ownership by Quarter for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.